Skip to main content
. 2012 Feb 1;4(1):77–87. doi: 10.3390/cancers4010077

Table 2.

Fotemustine post-temozolomide era.

Authors Number of Patients Schedule Toxicity Response Rate
Brandes et al. [22] 43 Standard 20.9 and 16% of patients 42%
Fabrini et al. [23] 50 Standard 4 and 1 patients 62%
Silvani et al. [24] 54 Combination of fotemustine and procarbazine 4 and 2 patients
Fabi et al. [26] 40 65 to 100 mg/m2 of fotemustine 8 and 6 patients 47.5%
Fabi et al. [26] 40 60 mg/m2 of fotemustine, every 3 weeks 3 and 4 patients 52.5%
Addeo et al. [9] 40 80 mg/m2 of fotemustine, every 2 weeks 7 and 3.5% of patients 65%